42.20 0.00 (0.00%)
Pre-Market: 4:16AM EST
|Bid||42.05 x 1400|
|Ask||42.22 x 800|
|Day's Range||41.93 - 42.56|
|52 Week Range||34.32 - 46.47|
|Beta (3Y Monthly)||0.52|
|PE Ratio (TTM)||22.66|
|Earnings Date||Apr 29, 2019 - May 3, 2019|
|Forward Dividend & Yield||1.44 (3.38%)|
|1y Target Est||44.46|
U.S. stocks ended in the green as investors digested minutes detailing the deliberations from the Federal Open Market Committee’s latest meeting.
The majority of S&P 500 companies that were concerned about the Jeff Bezos-led e-commerce giant in late 2017 are beating the broader market.
Pfizer (PFE) and Eli Lilly (LLY) announce that the higher dose of their investigational pain candidate, tanezumab, significantly reduces chronic low back pain in a late-stage study.
Ochsner Health System, Louisiana’s largest non-profit academic healthcare system, and Pfizer Inc (PFE) have entered into a multi-year strategic alliance to develop innovative models for clinical trials. Through this partnership, Pfizer and Ochsner — through its innovation lab, innovationOchsner (iO), in partnership with Ochsner Research — will explore ways to enhance the clinical trial experience and ease participation in clinical research for both patients and healthcare professionals. The alliance aims to create faster, improved access and connectivity to clinical trials for patients, with the ultimate goal of better experiences and outcomes.
On Sangamo (SGMO) Q4 conference call, investors will look into genome editing development and gene regulation technology platform, used for inventing genomic therapies to address unmet medical needs.
“Pfizer is dedicated to increasing access to biosimilars for patients suffering from serious illnesses and helping create a more sustainable healthcare system,” said Andreas Penk, M.D., regional president, Oncology International Developed Markets at Pfizer.
BALTIMORE, Feb. 19, 2019 /PRNewswire/ -- Gliknik Inc. today announced that it will receive a $15 million milestone payment from Pfizer Inc. (PFE) following the start of a Phase I clinical trial of Pfizer drug candidate PF-06755347, previously known as GL-2045, for the potential treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disorder. Gliknik and Pfizer entered into an exclusive worldwide licensing agreement in 2013.
A non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed on Tuesday. The drug was being tested in patients who had already used three different classes of painkillers but had not experienced enough relief or were intolerant to those treatments. Tanezumab belongs to a category of pain medications that target the nerve growth factor, a protein involved in the growth of nerve cells.
Pfizer and Eli Lilly said on Tuesday that a higher dose of their non-opioid drug tanezumab succeeded in reducing chronic low back pain in patients in a late-stage clinical study. However, a lower dose ...
NEW YORK and INDIANAPOLIS, Feb. 19, 2019 /PRNewswire/ -- Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP). In this study, CLBP was defined as low back pain that had persisted for more than three consecutive months. On average, they had CLBP for 10 years, and they reported a significant impact of their pain on their ability to function in everyday life.
Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.